A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging
Status:
Terminated
Trial end date:
2012-01-24
Target enrollment:
Participant gender:
Summary
This is a study of safinamide, an investigational drug for Parkinson disease (PD). Safinamide
is being developed as add-on therapy for the treatment of Parkinson disease. It is theorized
that safinamide acts by increasing the available dopamine in those areas of the brain where
dopamine is decreased as a result of Parkinson;s Disease. . Dopamine in the brain is involved
in controlling body movements. Safinamide has been extensively studied in animals, and has
been shown to increase the level of dopamine in these animals. Safinamide has also been
tested in patients with Parkinson disease. The goal of this research trial is to see if
safinamide is safe and well tolerated and to better understand how it affects the dopamine
system in the brain in individuals with Parkinson disease. Data from this trial may provide
essential information about the effectiveness and safety of these doses of safinamide in
patients with early Parkinson disease, who are already receiving a stable dose of their
normal Parkinson disease treatment.